Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Previous Speakers

Dr.Khushnooda Ramzan

Dr.Khushnooda Ramzan

King Faisal Specialist Hospital and Research Center UAE

Dr.Rezvan Mirzaei

Dr.Rezvan Mirzaei

Iran University of Medical Sciences Iran

Fatemeh Hayati

Fatemeh Hayati

University Sains Malaysia UAE

Dr. Dharambir Sanghera

Dr. Dharambir Sanghera

Professor of Pediatrics University of Oklahoma USA

Dr. Bahar Mahjoubi

Dr. Bahar Mahjoubi

Iran University of Medical Sciences Canada

Duaa Momani

Duaa Momani

Jordan University of Science and Technology Jordan

Eugenio Luigi Iorio

Eugenio Luigi Iorio

Professor President of International Observatory of Oxidative Stress Italy

Alessandra Pontillo

Alessandra Pontillo

Professor Universidade de Sao Paulo Brazil

Cystic fibrosis 2018

About Conference

This conference is directed toward basic scientists, clinical researchers, drug company representatives and trainees in CF analysis.

The goal is to bridge the newest advances in basic discovery with therapeutic development of latest treatments to enhance the lives of individuals with CF worldwide. The conference can specialize in a broad array of topics, including:

•Understanding CFTR structure and performance, particularly concerning rare mutations.

•Host and infective agent interactions.

•Development of novel therapeutic approaches, such as gene editing and nucleic acid delivery, to correct the essential defect in all people with CF.

•Development of tools, model systems and alternative resources to change analysis, drug discovery and customized drugs.

Why to attend ?

The conference series gives a collaboration and academic forum for CF professionals to assist advance CF analysis and care. The annual meeting brings along scientists, clinicians and caregivers from around the world to discuss and share ideas on the newest advances in CF analysis, care and drug development and to exchange ideas regarding ways to enhance the health and quality of life for individuals with CF

Target Audience:

  • Directors/CEO & Research Scientists
  • Pulmonologists, Respiratory Therapists & Pediatricians
  • Lung and Respiratory Researchers
  • Respiratory Faculty and Students
  • Lung and Respiratory Associations and Societies
  • Thoracic Surgeons, Radiologists
  • Business Entrepreneurs
  • Medical and Nursing Students, Professors
  • Postdoctoral fellows and Trainees
  • Diagnostic laboratory professionals
  • Pharmaceutical Professionals
  • Medical devices manufacturing companies

Sessions and Tracks

     Track 1: Clinical Cystic fibrosis

 

Cystic fibrosis (CF) is that the most typical, critical, recessively inherited disorder of Caucasian populations process of diagnostics. Genotyping technology has some limitations which  includes the choice of mutations to be tested, and also the clinical context in which the test is administered .These manifestations can all influence how genetic information is It is often challenging in clinical Cystic fibrosis (CF) to interpret molecular genetic results, and to integrate them in the interpreted. Neonates may have meconium ileus or, rarely, have some other features such as anasarca. Patients diagnosed are more likely to have pancreatic insufficiency when diagnosed later in childhood or in adulthood and often present with chronic cough and sputum production. Approximately 10% of patients with Cystic fibrosis remain pancreatic sufficient; these patients tend to have a milder course.

The importance of communication between clinicians and medical genetic laboratories is highlighted. The results of clinical trials and their implications should be reported in a manner that can be understandable to the clinicians caring for CF patients.

      1.1 Prognostic score

      1.2Medications

      1.3 Gastro Intestinal tract manifestation

      1.4 Mechanism of pathogenesis

      1.5 Chemical and cellular mechanism

 

     Track 2: Microbial Epidemiology

 

Recent advances in clinical care and disease-specific therapies have raised the lifetime and quality of life among folks with Cystic fibrosis (CF). Recent advances in clinical care and disease-specific therapies have raised the lifetime and quality of life among folks with Cystic fibrosis (CF). infection of the airways remains the first explanation for morbidity and mortality in persons with Cystic fibrosis (CF) but, deciding epidemiological trends in CF biological science is difficult attributable to lack of reliable historical knowledge for a few pathogens; changes in reportage strategies; variations in sampling strategies, microbiologic techniques, and culture frequency; and therefore the patient population studied microbial epidemiology.

       2.1  Cause of morbidity and mortality

       2.2 Mutations

       2.3 Exacerbations in Cystic fibrosis  

     2.4  Microbiological diagnosis

 

Track 3: Cystic fibrosis and Diabetes

 

CFRD is a distinct variety of diabetes having features of both Type 1 and Type 2 diabetes. The onset is insidious and therefore the glycaemic status varies being influenced by the clinical state of the patient. Delaying the diagnosis can result in an evitable deterioration in both respiratory function and clinical status. Hence the requirement for regular screening by annual glucose tolerance tests once the age of 12 years. Resources of both the Specialist CF and Diabetes Teams are unit essential for optimal management

      3.1 Glucose abnormalities in Cystic fibrosis

      3.2 Nutritional and diabetic care

      3.3 Oral glucose tolerance test

      3.4 Monitoring

 

 Track 4: Gastrointestinal and Cystic fibrosis

 

We have utilized in situ union to localize expression of the CF transmembrane electrical phenomenon regulator (CFTR) factor within the human gastrointestinal tract and associated organs. The abdomen exhibits a coffee level of CFTR expression throughout stomach membrane. within the gut, expression is comparatively high within the small intestine, with a decreasing gradient of expression on the sepulture to tip axis. The cells of the Brunner's glands specific high levels of CFTR informational RNA. Additionally, there's a little population of extremely positive cells scattered along the epithelium within the small intestine (duodenum and jejunum), however not within the ileum. These cells don't represent endocrine cells, as determined by lack of colocalization with associate degree endocrine-specific marker. The distribution of CFTR informational RNA within the colon is comparable to the tiny gut (small intestine), with highest level of expression within the epithelial cells at the bottom of the crypts. within the pancreatic gland, CFTR is expressed at high levels within the tiny, intercalated ducts and at lower levels within the interlobular ducts. CFTR transcripts are expressed at uniformly high levels within the epithelium of the gallbladder. Throughout the GI tract, CFTR expression is raised in mucosal epithelial cells that are close to body fluid nodules.

 4.1 Nested Reverse Transcriptase polymer chain reaction

 4.2 Oral calorie supplements

 4.3 Laser assisted micro dissection

 4.4 In situ hybridization

 4.5 Pancreatic Enzyme Replacement Therapy

 

Track 5: Cystic fibrosis and Neonatology

 

Cystic fibrosis (CF) is that the most typical multisystem, autosomal-recessive congenital disease resulting in premature death. Several patients with Cystic fibrosis is undernourished at the time of diagnosing. New-born screening and early treatment might avert the growth of a nutritional deficiency Neonatal screening for CF differs markedly from that for alternative diseases with regard to the checking ways and therefore the procedure to be followed if an initial screening test is positive. CF is that the solely illness that genetic studies are performed.

The goal of screening for Cystic fibrosis isn't to avert an on the spot danger to health, however rather to stabilize the patient’s condition over the future. To spare parents supernumerary worry, the time between the communication of a positive screening result and therefore the initiation of more testing should be unbroken as short as attainable

5.1 Neonatal screening for Cystic fibrosis

5.2 Genetic testing for Cystic fibrosis

5.3 Nutritional therapy

5.4 Genetic Counselling

 

Track 6: Cystic fibrosis and Respiratory care

 

Patients with simple meconium ileus usually present with abdominal distension or abdominal enlargement at birth, eventually progressing to failure to pass Approximately 7-10% of patients with Cystic fibrosis have Meconium ileus. meconium, bilious vomiting, and progressive abdominal enlargement.

Patients with severe meconium ileus present more dramatically at birth with complicated abdominal distention, sometimes accompanied by abdominal wall erythema and edema. Abdominal distention could also be severe enough to cause metastasis distress.. Other GI signs in neonates (babies) incorporate intestinal obstruction during childbirth and different surgical discoveries (eg, volvulus, intestinal atresia, aperture, meconium peritonitis). Less usually, section of meconium might be postponed (more than 24-48 hours after birth) or cholestatic jaundice might be extent in the patients.

 

6.1 Sputum expectoration in older children

6.2 Pathophysiology of Cystic fibrosis

6.3 Gene Replacement Therapy

6.4 Chronic Maintenance Therapy

 

Track 7: Immunology and Pulmology

 

The  combination of all the immunologic abnormalities delineated in CF seems to possess a final common pathway through effects on neutrophils. Potent neutrophil chemotactic factors are made as a results of antibody-antigen interactions resulting in complement activation and therefore the generation of C5a and therefore the several cytokines free as a results of cellular immune responses resulting in neutrophil flow and activation. Additionally, the product of microorganism metabolism fMLP additionally produces neutrophil chemotaxis. The activated neutrophils unleash a variety of proteases and chemical element radicals (oxygen) that directly harm tissues. It can, therefore, be hypothesized that the excessive response is directly conducive to the tissue harm. Indeed, it's even attainable that this can be the principal explanation for the respiratory defect while not invoking any direct influence of the infecting organisms. This, of course, has major implications for approaches to medical aid. presently the most focus is on

7.1 Bronchoscopy and anaesthesia

7.2 Performance Diagnostics

7.3 Structural Imaging

7.4 Immunoglobulin Replacement therapy

7.5 Allergen Immunotherapy

 

Track 8: Distal Intestinal Obstruction Syndrome ( DIOS ) AND Cystic Fibrosis

 

Complete or incomplete blockage by mucilaginous soiled material within the terminal small intestine and proximal colon – distal intestinal blockage syndrome (DIOS) – is a common complication in Cystic fibrosis. DIOS is principally seen in patients with pancreatic insufficiency.

Meconium intestinal obstruction at birth, distal intestinal blockage syndrome (DIOS), and constipation are an interconnected cluster of intestinal blockage syndromes with a variable severity of obstruction that happens in Cystic fibrosis patients. DIOS and constipation are oftentimes seen in Cystic fibrosis patients, particularly later in life; genetic, dietary, and alternative associations are explored. The pathological process of DIOS is part thanks to loss of CFTR perform within the viscus wherever it regulates chloride secretion from the crypts, carbonate secretion from Brunner’s glands and metallic element transport. ileus has been reported as a significant explanation for mortality in CF mice with severe CFTR mutations.  Additionally to defective chloride secretion, CFTR regulates EnaC, NHE3 and ion exchangers resulting in excess absorption and reduced secretion of fluid, that contributes to viscus obstruction.

8.1 Ultrasound and Computed tomography (CT)

8.2 Differential diagnostics

8.3 Radiography

 

Track 9:  Disorders and Diagnostics

 

Cystic fibrosis is a multisystem disorder with a large spectrum of clinical manifestations, and patients might gift to a variety of medical specialists. A whole diagnostic analysis for CF concern to embrace a sweat chloride test, a genetic or carrier test, and a clinical analysis of the patients with Cystic fibrosis.

Most children currently screened for CF at birth through newborn screening and also the majority  are diagnosed by age two. However, some people with CF are diagnosed as adults.

9.1 New born screening

9.2 Physical therapy

9.3 Antenatal screening

9.4 Monitoring Cystic fibrosis

9.5 Performance diagnostics

 

Track 10: Cystic fibrosis Treatment and Management

 

Pulmonary aggravation have vital outcomes in Cystic fibrosis (CF), each in terms of current morbidity similarly as implications for future morbidity associated mortality. The use of an indwelling intravenous infusion set for the house administration of potent antibiotics has been quite self-made within the medical care of the chronic bronchopulmonary infection related to Cystic fibrosis. Different Techniques included:

Airway clearance techniques (ACTs) loosen thick, sticky secretion therefore it will be cleared from your lungs by coughing or huffing. Clearing the airways could facilitate decrease respiratory infections and improve respiratory organ function.

CFTR (cystic pathology transmembrane electrical phenomenon regulator) modulator therapies are designed to correct the operation of the defective biomolecule created by the CF gene. as a result of |completely different mutations cause different defects within the biomolecule, the medications that are developed thus far are effective solely in individuals with specific mutations.

10.1 Nutritional care

10.2 Rehabilitation therapy

10.3 Smoking cessation

10.4 Help after diagnosis

10.5 Medications

10.6 Diet and airway clearance

 

Track 11: Gene therapy and Cystic fibrosis

 

Basically, biotechnology refers to an honest vary of things, including producing large numbers of human proteins etc. to treat of us with illnesses equivalent to genetic disorder. Gene- splicing involves shot a gene into a cell therefore the cell produces any substances that sequence codes for. Thus gene splicing is going to be used in organism, plants and animals. Gene treatment can also be used to treat of us with diseases but in extremely different technique. If scientists notice one sequence that, once faulty, is responsible for a condition equivalent to fibrocystic disease of the exocrine gland then they will be in an exceedingly position to treat of us with that ailment by giving them doses of the 'correct' form which is required for that sequence.

11.1 Gene expression

11.2 Gene transfer agents (GTA’s)

11.3 Non-viral approach

11.4 New treatment modalities for Cystic fibrosis

 

Track 12: Genetics and Cystic fibrosis

 

The development of monogenic disorder (CF) is caused by dysfunction of a protein that transports sodium and chloride across cell membranes. This protein is termed as the Cystic fibrosis transmembrane conductance regulator (CFTR). The impairment happens once there's a mutation within the monogenic disorder(CF) transmembrane electrical phenomenon regulator (CFTR) sequence, that is that the sequence liable for the movements of charged particles referred to as chloride ions into and out of cells. Since biological science is liable for the event of monogenic disorder (CF), the condition is hereditary. However, there's no transmission mechanism and also the genetic heredity method is extremely complicated.

Cystic fibrosis runs in families in an autosomic chromosome recessive pattern, which implies each copies of the sequence in every cell have mutations. In CF cases, every parent has one CFTR (mutated) sequence and one traditional CF sequence, however if the traditional sequence dominates the parent might never know that they are carrying sequence gene and square measure potential “carriers.” A child solely gets CF once the faulty CFTR sequence from each parent is genetically passed down

12.1 Cystic fibrosis gene pool

12.2 Complementary DNA hybridization

12.3 CFTR gene mutation

12.4 Inheritance pattern of Cystic fibrosis

 

Track 13: Aspects and Complications in Surgery of Cystic fibrosis.

 

Cystic fibrosis (CF) incorporates a variety of pulmonary manifestations that embrace respiratory illness, bronchiectasis, hemoptysis, and pneumothorax. Although newer therapies have greatly improved survival of patients with CF, surgical interventions for definitive treatment of those sequelae are usually needed. Many reports have illustrated that, with this advances within the perioperative treatment and care of CF patients, surgical interventions for these pulmonary manifestations could also be performed safely, leading to a greatly improved quality of life. Also, though enhancements in pulmonary transplantation supply new hope for definitive treatment of those patients with Cystic fibrosis of the pancreas, special issues concerning different surgical problems, comparable to the prevalence of oesophageal reflux, need to be self-addressed.

Although the patient with Cystic fibrosis of the pancreas is mostly at a far bigger risk for the complications of surgery than the conventional patient, expertise within the management of these patients has greatly improved the outlook. However, in most instances, surgical management of the patient with Cystic fibrosis of the pancreas represents palliation, since these patients typically die of the medical complications of their sickness. Any controlled studies are required to totally measure the role of surgery within the sequelas of Cystic fibrosis.

13.1 Efficiency and Safety of Surgical Indention to patients

13.2 Chronic rhinosinusitis with Nasal polyps

13.3 Scoliosis surgery

13.4 Gastro Intestinal tract and Sino nasal Complications

 

Track 14: Clinical trials in Cystic fibrosis

Clinical trials are an important  part of making certain innovative medication may be created out there to the those who really want them whereas making certain they're safe and effective. Clinical trials are of chief importance in patients with Cystic fibrosis. The current status of drug development in Cystic fibrosis and future directions proves to be interesting. Methods for pre-clinical testing of drugs with potential activity in Cystic fibrosis patients include relevant animal models. Study design options for phase II and phase III studies associating CF patients are given, including required patient numbers, safety issues and surrogate end point parameters for drugs, tested for different disease manifestations. Finally, regulatory issues for licensing new therapies for CF patients are to be done.

14.1 Lifestyle and home remedies

14.1 Medical care

14.2 Pre-clinical drug testing

14.3 Chronic Stabilization therapy

14.4 Cystic fibrosis and Anaesthesia

 

Market Analysis

Conference series Ltd. invitations all the participants through the world to join at "International Cystic fibrosis Conference" which is going to held during September 21-22, 2018 Dubai, UAE which encompasses keynote sessions, oral presentation, Poster presentation and Exhibitions. the major theme of the conference is unveiling the amelioration in Cystic fibrosis that covers current and developing research on Cystic fibrosis and its connected complications and cure.

  • The international Cystic fibrosis market is anticipated to achieve USD 13.9 billion by 2025, as per a recent report by Grand View Research, Inc. The rising prevalence of Cystic fibrosis (CF) globally, research & development activities undertaken by key players and favourable initiatives undertaken by non-profit organizations are expected to step  up the market over the forecast course.
  • The CFTR modulator segment emerged as the largest segment in 2016 and also the same segment is anticipated to witness quickest growth over following 8 years thanks to the approval of CFTR modulator, Orkambi and also the presence of various investigational compounds beneath the pipeline. Oral route of administration emerged as the largest phase with revenue of USD 2,266.4 million due to the ease of administration and convenience.

Target Audience for CRISPR 2018 will be personnel from both industrial and academic fields which include; Directors/Managers, Head of Departmental, Presidents/Vice Presidents, CEO, Professors, Associate and Assistant professors, Research Scholars and students from the related fields.

 

                                               

Target Audience

Industry        40%

Academia     50%

Others          10%

 

The market for CF Therapeutics is projected to point out a promising and remunerative growth within the next few years because of continuing R&D activities in this field. At present, there are more than 30-40 medication (including bronchodilators, antibiotics, NSAIDs, steroids and others) accessible  in the market. Further owing to continuing in depth analysis and development activities, a variety of medicines are expected to launch within the market in future period. Increasing world awareness for Cystic fibrosis therapy, technological advancements in the R&D and increase the prevalence of Cystic fibrosis are a number of the factors estimated as the major drivers for CF Therapeutics market. However, difficult pathophysiology, high price of treatment and R&D and increase in genetic mutation are a number of the factors expected to hinder the expansion of this market.

 

                                

Respiratory Care Devices Market worth 21.9 Billion USD by 2020

The respiratory care devices market is growing at a significant rate since the last decade. Growth in this market is mainly attributed to the high prevalence of respiratory diseases, rising aging population across the globe, high prevalence of smoking, rising urbanization and pollution levels, increasing incidences of preterm births, and lifestyle changes. However, lack of awareness and harmful effects of certain respiratory care devices on neonates are the major challenges in this market.

Drivers:

Some factors contributing to the growth of the market are:

  • Large patient population
  • Increase in the technological advancements
  • Increased disposable income in developing nations
  • Rising incidence of Cystic fibrosis.

Industry Insights

The global Cystic fibrosis therapeutics market size was calculated at USD 3.56 billion in 2016. Increasing prevalence of Cystic fibrosis (CF) combined with  rising treatment rate is one of the key factors anticipated to propel the demand for these therapeutics over the forecast course. Moreover, increase in R&D funding by each non-public & public organizations, rising range of initiatives undertaken by non-profit organizations, and presence of favourable compensation policies are  some of the crucial factors expected to drive the market within the coming few years.

According to the report published by Cystic fibrosis Foundation, the incidence of these hereditary disorders is continually growing. In the U.S., in 2015, there have been 28,983 patients as compared to the 26,366 patients in 2010. Increasing year-on-year growth in the count of patients further leads to deluge demand for efficient and effective CF therapeutics. a number of the commercially offered approved drug category are Cystic fibrosis Transmembrane Conductance Regulator (CFTR) modulators, bronchodilators medication, mucolytic medication, anti-infective, antibiotics (oral, inhaled, or parental feeding formulae), anti- inflammatory medication, and pancreatic supplements.

             

                     U.S. Cystic fibrosis therapeutics market, by drug class, 2014 - 2025 (USD Million)

 

Drug Class Insights

Based on the drug category, the market is metamerised into pancreatic enzyme supplements, mucolytics, bronchodilators, and CFTR modulators. the primary thought consideration the treatment of CF is maintaining the respiratory function whereas controlling its infections and clearing airways of mucus, managing the nutritional therapy, and controlling the complications. Kalydeco was the primary CFTR modulator drug, that was launched in 2012 within the U.S.  As of 2014, it had been the sole CFTR modulator drug within the market

In 2016, CFTR modulators accounted for the highest revenue with a share of roughly 47.3% owing to the launch of recent drug Orkambi. This drug is responsible for correcting the performance of defective protein caused by the CF gene. This drug category directly cures the underlying reason behind the illness. the product launch in 2015 is one of the key factors which will be accounted for its share. Moreover, CFTR modulators are  expected to grow with the profitable rate of 24.1% over the forecast course.

This drug category is anticipated to be the quickest growing section because of the growing range of drugs within the pipeline. a number of the CFTR modulators drugs mixtures that are in pipeline are as follows:

  • VX-445+tezacaftor+ivacaftor                                           
  • GLPG 2222                                         
  • VX-659+tezacaftor+ivacaftor                                               
  • QBW251
  • VX-152+tezacaftor+ivacaftor                                             
  • QBW251
  • VX-440+tezacaftor+ivacaftor                                               
  • Riociguat
  • Tezacaftor (VX-661)+Ivacaftor                                             
  • CTP-656 (Deuterated ivacaftor)
  • PTI-428,
  • QR-010

                                       

 

 Associative Organisation

Australia:

Cystic fibrosis Australia (CFA)

Europe:

Association Gregory Lemarchal, Build4 LifeCystic fibrosis Ireland (CFI), Child health International (CHI), Chloe Cotton Trust Fund, Cystic fibrosis Foundation Slovenia, Nederlands Cystic fibrosis Stichting, European Cystic fibrosis Society (ECFS), Mukolife.com, Cystic fibrosis Trust

North America:

Blooming Rose Foundation, Boomer Esiason Foundation, Breathe 4 Tomorrow Foundation (B4TF), Cystic fibrosis Research, Inc. (CFRI), Cystic-L, Cystic fibrosis Canada (CCFF), Cystic fibrosis Foundation (CFF), Cystic fibrosis Lifestyle Foundation (CFLF), Cystic fibrosis-Reaching Out Foundation, CysticLife.org (CL), Elizabeth Nash Foundation, Lungs for Life Foundation

International:

Cystic fibrosis Worldwide (CFW), CysticFibrosis.com, CysticLife.org (CL), Sharktank.org

    

Related conferences : 2nd International Conference on Medical and Clinical Microbiology July 16-17, 2018 Melbourne, Australia. 9th International Summit on Clinical Microbiology October 08-09, 2018 Zurich, Switzerland. 15th International Conference on Clinical Nutrition. 4th World Congress on Medical Imaging and Clinical Research. 4th World Congress on Public Health, Epidemiology & Nutrition. 7th International Conference on Epidemiology & Public Health. 8th International Conference on Epidemiology & Public Health. 12th International Conference on Pharmacoepidemiology and Clinical Research. 5th International Conference on Human Genetics and Genetic Disorders. 3rd World Congress on Neonatology & Neonatal Nursing. World Congress on Neonatal Research and Diagnosis. 6th International Conference on Lung and Respiratory Diseases. Annual Congress on Pulmonology & Respiratory Medicine. 10th Global Summit on Immunology and Cell biology. 8th International Conference and Exhibition on Cell & Gene Therapy.

 

     

Past Conference Report

Human Genetics 2017

Conference series LLC hosted World Congress on Human Genetics during Nov 7-8, 2016 Barcelona, Spain based on the theme “Genomic Revolution: A debate on Human Genetic Disorders & Diseases”.

Active participation and generous response was received from the Organizing Committee Members, scientists, researchers, as well as experts from Non-government organizations, and students from diverse groups who made this conference as one of the most successful and productive events in 2016 from Conference series LLC.

The conference was marked with several workshops, multiple sessions, Keynote presentations, panel discussions and Poster sessions. We received active participation from scientists, young and brilliant researchers, business delegates and talented student communities representing more than 35 countries, who have driven this event into the path of success.

The conference was initiated with a warm welcome note by Honorable guests and the Keynote forum. The proceedings went through interactive sessions and panel discussions headed by honourable Moderator Dr. E Sacide Caglayan, Ankara Yildirim Beyazit University, Turkey and Dr. Marta Stasiak, Medical University of Lodz, Poland for the conference.

The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following Speakers were highlighted as Keynote speakers:

Optimizing clinical understanding of genomic variants in autism and other disorders of development: E Robert Wassman, Lineagen Inc., USA

The clinical and personal utility of multi-gene analysis for severe skeletal dysplasias: Elaine Lyon, University of Utah, USA

Pentagenic haplotype-related cholesterolemic phenotype in Alzheimer’s disease: Ramon Cacabelos, EuroEspes Biomedical Research Center, Spain

Conference series LLC has taken the privilege of felicitating Human Genetics 2016 Organizing Committee, Keynote Speakers who supported for the success of this event. Conference series LLC, on behalf of the Organizing Committee congratulates the Best Poster awardees for their outstanding performance in the field of Human Genetics and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavours.

Poster Judging was done by: Dr. Byung-Dong Kim, Seoul National University, Korea and Dr.Ramon Cacabelos, EuroEspes Biomedical Research Center, Spain. Best Poster Award was received by: Ms.Jin Won Seong, Ewha Womans University, South Korea Human Genetics 2016 was sponsored by one of the leading Company EuroEspes Biomedical Research Center, Spain.

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance towards the success of Human Genetics 2016.

With the unique feedback from the conference, Conference Series LLC would like to announce the commencement of the " International Cystic Fibrosis Conference: A cure for all”, during September September 20-21, 2018 Dubai, UAE

For More details visit: https://cysticfibrosis.conferenceseries.com/

 


Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date September 20-21, 2018

Speaker Opportunity

Supported By

1. Journal of Clinical & Medical Genomics 2. Journal of Pulmonary & Respiratory Medicine 3. Cystic Fibrosis Research Articles

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by


Keytopics

  • Type1 Diabetes
  • Abdominal Distension
  • Airway Clearance
  • Allergen Immunotherapy
  • Anaesthesia
  • Antenatal Screening
  • Bronchiectasis
  • Bronchioscopy
  • CFRD
  • Chronic Bronchopulmonary Infection
  • Chronic Maintenance Therapy
  • Chronic Rhinosinusitis
  • Chronic Stabilization Therapy
  • Clinical Cysticfibrosis
  • Clinical Trials
  • Cystic Fibrosis Therapeutics
  • Cytokines
  • DIOS
  • Epidemiology
  • Fibrocystic Disease
  • Gastro Intestinal Tract Manifestation
  • Gene Replacement Therapy
  • Gene-splicing
  • Genetic Counselling
  • Hereditary Genetics
  • Inheritance Pattern
  • Intestinal Atresia
  • Intestinal Obstruction
  • Laser Assisted Micro Dissection
  • Medications
  • Metastasis Distress
  • Microbiological Diagnosis
  • Monogenic Disorder
  • Mucolytic Medication
  • Mutations
  • Nasal Polyps
  • Neonatal Screening
  • Nutritional And Diabetic Care
  • Palliation
  • Pancreatic Enzyme Replacement Therapy
  • Pancreatic Sufficiency
  • Performance Diagnostics
  • Pre-clinical Drug Testing
  • Pulmonary Aggravation
  • Pulmonary Transplantation
  • Radiography
  • Rehabilitation Therapy
  • Respiratory Illness
  • Scoliosis Surgery
  • Smoking Cessation
  • Structural Imaging
  • Type2 Diabetes
  • Ultrasound And Computed Tomography